Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Semin Radiat Oncol. 2011 Oct;21(4):294–302. doi: 10.1016/j.semradonc.2011.05.004

Table 1. Summary of few landmark studies.

Salem et al Hilgard et al Salem et al Kennedy et al Hendlisz et al
Purpose To assess clinical outcomes of HCC patients treated with 90Y To assess clinical outcomes of HCC patients treated with 90Y in Europe To compare the effectiveness of 90Y vs. TACE in HCC patients To assess 90Y as a salvage therapy for unresectable colorectal liver metastases Prospective randomized phase III trial comparing FU alone (arm A) with 90Y+ FU (arm B) for unresectable CRC metastases
Disease HCC HCC HCC CRC metastases CRC metastases
Patients 291 108 90Y: 123
TACE: 122		 208 Arm A: 23
Arm B: 21
Response rate WHO: 42%
EASL: 57%		 EASL: 40% 90Y: 49%
TACE: 36%		 CT: 35%
PET: 91%
CAE: 70%		 -
TTP (months) 7.9 10 90Y: 13.3
TACE: 8.4		 - Arm A: 2.1
Arm B: 4.5
Survival (months) Child-Pugh A:17.2
Child-Pugh B:7.7		 16.4 90Y:20.5
TACE: 17.4		 Responders:10.5
Nonresponders: 4.5		 Arm A: 7.3
Arm B: 10